These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1227 related items for PubMed ID: 23838676

  • 1. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [Abstract] [Full Text] [Related]

  • 2. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT, Yang KX, Yu J, Cao YY, Ren JS, Hao JJ, Pan BQ, Ma S, Yang LY, Cai Y, Wang MR, Zhang Y.
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G, Zhao Q, Zhang M, Fan T, Liu M, Shi X, Ren Y, Wang Y, Zhou J, Lu Z.
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [Abstract] [Full Text] [Related]

  • 4. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z, Yang Z, Passaniti A, Lapidus RG, Liu X, Cullen KJ, Dan HC.
    Oncotarget; 2016 May 31; 7(22):31892-906. PubMed ID: 26895469
    [Abstract] [Full Text] [Related]

  • 5. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
    Gen Y, Yasui K, Nishikawa T, Yoshikawa T.
    Cancer Sci; 2013 Jul 31; 104(7):810-6. PubMed ID: 23510069
    [Abstract] [Full Text] [Related]

  • 6. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
    Alqurashi N, Hashimi SM, Alowaidi F, Ivanovski S, Wei MQ.
    Oncol Rep; 2018 Aug 31; 40(2):1083-1092. PubMed ID: 29845289
    [Abstract] [Full Text] [Related]

  • 7. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X, Lai P, Zhang Z, Huang M, Wang L, Yin M, Jin D, Zhou R, Bai X.
    Oncol Rep; 2014 Jul 31; 32(1):382-8. PubMed ID: 24840134
    [Abstract] [Full Text] [Related]

  • 8. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H, Lin J, Wang X, Yao G, Wang L, Zheng H, Yang C, Jia C, Liu A, Bai X.
    Breast Cancer Res Treat; 2012 Aug 31; 134(3):1057-66. PubMed ID: 22476852
    [Abstract] [Full Text] [Related]

  • 9. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J, Shannon C, Mohan A, Laurent D, Murali R, Jhanwar-Uniyal M.
    Int J Oncol; 2016 Mar 31; 48(3):1045-52. PubMed ID: 26719046
    [Abstract] [Full Text] [Related]

  • 10. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J.
    PLoS One; 2015 Mar 31; 10(7):e0132880. PubMed ID: 26176608
    [Abstract] [Full Text] [Related]

  • 11. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
    Peng KZ, Ke Y, Zhao Q, Tian F, Liu HM, Hou G, Lu Z.
    Biochem Pharmacol; 2017 Sep 15; 140():16-27. PubMed ID: 28539264
    [Abstract] [Full Text] [Related]

  • 12. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF.
    Cell Death Dis; 2014 Mar 13; 5(3):e1114. PubMed ID: 24625973
    [Abstract] [Full Text] [Related]

  • 13. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q, Qin S, Zhang H, Liu B, Qin J, Wang X, Zhang R, Liu C, Dong X, Zhang S, Huang S, Chen L.
    J Cell Physiol; 2018 Jan 13; 233(1):516-529. PubMed ID: 28300280
    [Abstract] [Full Text] [Related]

  • 14. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.
    Blood; 2012 Sep 27; 120(13):2679-89. PubMed ID: 22826565
    [Abstract] [Full Text] [Related]

  • 15. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ.
    Gynecol Oncol; 2014 Feb 27; 132(2):468-73. PubMed ID: 24316308
    [Abstract] [Full Text] [Related]

  • 16. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M, Hussain AR, Bavi P, Ahmed SO, Al Sobhi SS, Al-Dayel F, Uddin S, Al-Kuraya KS.
    Carcinogenesis; 2014 Jul 27; 35(7):1564-72. PubMed ID: 24583924
    [Abstract] [Full Text] [Related]

  • 17. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
    Gordeev SA, Bykova TV, Zubova SG, Bystrova OA, Martynova MG, Pospelov VA, Pospelova TV.
    Oncotarget; 2015 Dec 29; 6(42):44905-26. PubMed ID: 26636543
    [Abstract] [Full Text] [Related]

  • 18. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    Sathe A, Chalaud G, Oppolzer I, Wong KY, von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA, Nawroth R.
    PLoS One; 2018 Dec 29; 13(1):e0190854. PubMed ID: 29357370
    [Abstract] [Full Text] [Related]

  • 19. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X, Wang X, Qin L, Xu T, Zhu Z, Zhong S, Zhang M, Shen Z.
    Urology; 2015 Jan 29; 85(1):273.e1-7. PubMed ID: 25440763
    [Abstract] [Full Text] [Related]

  • 20. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J.
    Cell Cycle; 2015 Jan 29; 14(2):232-42. PubMed ID: 25607647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.